QC
CPRX icon

Quantedge Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Quantedge Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-324,700
Closed -$5.38M – 137
2023
Q1 		$5.38M Sell
324,700
-30,300
-9% -$500K 2.1% 10
2022
Q4 		$6.6M Sell
355,000
-148,700
-30% -$2.29M 2.21% 7
2022
Q3 		$6.46M Sell
503,700
-164,200
-25% -$1.95M 1.99% 4
2022
Q2 		$4.68M Buy
667,900
+70,600
+12% +$518K 0.94% 31
2022
Q1 		$4.95M Buy
597,300
+237,200
+66% +$1.68M 1.46% 16
2021
Q4 		$2.44M Buy
+360,100
New +$2.37M 1.03% 26

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Quantedge Capital's CPRX Position: Q2 2023 in Review

Quantedge Capital sold out of Catalyst Pharmaceutical (CPRX) in Q2 2023, closing a stake of 324,700 shares — an estimated $5.38M sold.

Quantedge Capital first reported a position in CPRX in Q4 2021 and held it in 6 quarters. The position peaked at $6.6M in Q4 2022. 248 funds tracked by Wall St. Rank hold CPRX as of Q2 2023.

  • Quantedge Capital reported no remaining Catalyst Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Quantedge Capital sold 324,700 Catalyst Pharmaceutical shares in Q2 2023, an estimated $5.38M.
  • Quantedge Capital first reported a position in Catalyst Pharmaceutical in Q4 2021 and held it in 6 quarters.
  • Quantedge Capital's Catalyst Pharmaceutical position peaked at $6.6M in Q4 2022.
  • 248 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2023.

Based on Quantedge Capital's 13F filing for Q2 2023, filed 11 Aug 2023.